Vladimir Coric

Summary

Affiliation: Bristol-Myers Squibb
Country: USA

Publications

  1. ncbi Multicenter, randomized, double-blind, active comparator and placebo-controlled trial of a corticotropin-releasing factor receptor-1 antagonist in generalized anxiety disorder
    Vladimir Coric
    Bristol Myers Squibb Company, Neuroscience Global Clinical Research, Wallingford, Connecticut 06492, USA
    Depress Anxiety 27:417-25. 2010
  2. ncbi Safety and tolerability of the γ-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease
    Vladimir Coric
    Neuroscience Global Clinical Research, Bristol Myers Squibb, Wallingford, Connecticut 06492, USA
    Arch Neurol 69:1430-40. 2012

Detail Information

Publications2

  1. ncbi Multicenter, randomized, double-blind, active comparator and placebo-controlled trial of a corticotropin-releasing factor receptor-1 antagonist in generalized anxiety disorder
    Vladimir Coric
    Bristol Myers Squibb Company, Neuroscience Global Clinical Research, Wallingford, Connecticut 06492, USA
    Depress Anxiety 27:417-25. 2010
    ..This study was designed to determine the safety and efficacy of pexacerfont, a selective CRF-1 receptor antagonist, in the treatment of generalized anxiety disorder (GAD)...
  2. ncbi Safety and tolerability of the γ-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease
    Vladimir Coric
    Neuroscience Global Clinical Research, Bristol Myers Squibb, Wallingford, Connecticut 06492, USA
    Arch Neurol 69:1430-40. 2012
    ..To assess the safety, tolerability, and pharmacokinetic and pharmacodynamic effects of the -secretase inhibitor avagacestat in patients with mild to moderate Alzheimer disease (AD)...